Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.

RPEP-044272019Pramil, Elodie; Herbi Bastian, Linda; Denèfle, Thomas; Nemati, Fariba; Xiao, Malina; Lardé, Eva; Maloum, Karim; Roos-Weil, Damien; Chapiro, Elise; Le Garff-Tavernier, Magali; Davi, Frédéric; Decaudin, Didier; Sarfati, Marika; Nguyen-Khac, Florence; Merle-Béral, Hélène; Karoyan, Philippe; Susin, Santos A

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.

Blood advances, 3(20), 2920-2933

View on PubMed ↗Publisher’s paper ↗

Citation

Pramil, Elodie; Herbi Bastian, Linda; Denèfle, Thomas; Nemati, Fariba; Xiao, Malina; Lardé, Eva; Maloum, Karim; Roos-Weil, Damien; Chapiro, Elise; Le Garff-Tavernier, Magali; Davi, Frédéric; Decaudin, Didier; Sarfati, Marika; Nguyen-Khac, Florence; Merle-Béral, Hélène; Karoyan, Philippe; Susin, Santos A. (2019). Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.. Blood advances, 3(20), 2920-2933. https://doi.org/10.1182/bloodadvances.2019000350